This study assessed the effect of bezafibrate on monocyte secretory function and systemic
inflammation in patients with impaired fasting glucose (IFG), comparing this effect with that …

The aim of this study was to compare the action of fenofibrate on monocyte cytokine release
between patients with isolated mixed dyslipidemia and dyslipidemia coexisting …

Context: Apart from lowering lipid levels, peroxisome proliferator-activated receptor (PPAR)
α activators (fibrates) produce many other favorable effects that may contribute to their …

To investigate whether the lowering of triglyceride levels has beneficial effects on glucose
metabolism, we studied 13 nondiabetic men with combined hyperlipidemia (phenotype IIB) …

Non-insuiin-dependent diabetes mellitus (NIDDM) is characterized by hyperglycemia
secondary to increased hepatic glucose output and impaired extrahepatic insulin sensitivity …

The clinical efficacy of bezafibrate was examined with special reference to glucose
metabolism in patients with type 2 diabetes mellitus (DM2). In protocol 1, 342 patients with …

Background Fibrates were found to reduce cytokine release and low-grade inflammation in
patients with impaired glucose tolerance. The aim of this study was to investigate whether …

The aim of the present study was to investigate the effect of bezafibrate on insulin sensitivity
and insulin secretion in 30 non-obese Japanese type 2 diabetic patients with …

The effects of bezafibrate 400 mg day− 1 or placebo administered for 3 months, were
compared in 36 patients with stable Type 1 diabetes and hypercholesterolaemia and/or …

Although it has been reported that bezafibrate influences carbohydrate metabolism, this
possibility has never been properly evaluated in a controlled clinical trial. In this study we …